Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 428169, 13 pages
http://dx.doi.org/10.1155/2015/428169
Review Article

Adverse Events of Monoclonal Antibodies Used for Cancer Therapy

1Department of Oncology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China
2Department of Allergy, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China

Received 6 August 2014; Accepted 24 August 2014

Academic Editor: Ji-Fu Wei

Copyright © 2015 Mei Guan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Muraro, G. Roberts, and M. Worm, “Anaphylaxis: guidelines from the European Academy of Allergy and Clinical Immunology,” Allergy, vol. 69, pp. 1026–1045, 2014. View at Google Scholar
  2. Zevalin, FDA: Full Prescribing Information. Adverse Reactions, 2013, http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125019s0156.pdf.
  3. Bexxar, FDA: Full prescribing information. Adverse reactions, 2013, http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125011s102lbl.pdf.
  4. E. R. Gomes and P. Demoly, “Epidemiology of hypersensitivity drug reactions,” Current Opinion in Allergy and Clinical Immunology, vol. 5, no. 4, pp. 309–316, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. E. Kimby, “Tolerability and safety of rituximab (MabThera),” Cancer Treatment Reviews, vol. 31, no. 6, pp. 456–473, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Castells, “Rapid desensitization for hypersensitivity reactions to medications,” Immunology and Allergy Clinics of North America, vol. 29, no. 3, pp. 585–606, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. C. H. Chung, B. Mirakhur, E. Chan et al., “Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3- galactose,” The New England Journal of Medicine, vol. 358, no. 11, pp. 1109–1117, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Jankowitz, J. Joyce, and S. A. Jacobs, “Anaphylaxis after administration of ibritumomab tiuxetan for follicular non-Hodgkin lymphoma,” Clinical Nuclear Medicine, vol. 33, no. 2, pp. 94–96, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Rispens, N. I. L. Derksen, S. P. Commins, T. A. Platts-Mills, and R. C. Aalberse, “IgE Pro- ductiontoa -Gal is accompanied by elevated levels of specific IgG1 antibodies and low amounts of IgE to blood group B,” PLoS ONE, vol. 8, no. 2, Article ID e55566, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. E. A. Berg, T. A. Platts-Mills, and S. P. Commins, “Drug allergens and food—the cetuximab and galactose-α-1, 3-galactose story,” Annals of Allergy, Asthma & Immunology, vol. 112, no. 2, pp. 97–101, 2014. View at Google Scholar
  11. C. H. Chung, B. Mirakhur, E. Chan et al., “Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3- galactose,” The New England Journal of Medicine, vol. 358, no. 11, pp. 1109–1117, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. P. McLaughlin, A. J. Grillo-López, B. K. Link et al., “Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program,” Journal of Clinical Oncology, vol. 16, no. 8, pp. 2825–2833, 1998. View at Google Scholar · View at Scopus
  13. A. Sandhu, A. Harford, and P. Singh, “Is thymoglobulin or rituximab the cause of this serum sickness? A case report of serum sickness dilemma and literature review,” Case Reports in Medicine, vol. 2012, Article ID 234515, 7 pages, 2012. View at Publisher · View at Google Scholar
  14. G. Le Guenno, M. Ruivard, L. Charra, and P. Philippe, “Rituximab-induced serum sickness in refractory immune thrombocytopenic purpura,” Internal Medicine Journal, vol. 41, no. 2, pp. 202–205, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. M. J. Keating, I. Flinn, V. Jain et al., “Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study,” Blood, vol. 99, no. 10, pp. 3554–3561, 2002. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Shablak and A. Conn, “A case of fatal cetuximab-induced interstitial lung disease during the first weeks of treatment,” Targeted Oncology, vol. 9, no. 2, pp. 177–180, 2014. View at Publisher · View at Google Scholar
  17. D. Cunningham, Y. Humblet, S. Siena et al., “Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer,” The New England Journal of Medicine, vol. 351, no. 4, pp. 337–345, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Van Cutsem, M. Peeters, S. Siena et al., “Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer,” Journal of Clinical Oncology, vol. 25, no. 13, pp. 1658–1664, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. T. J. Price, M. Peeters, T. W. Kim et al., “Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised , multicentre , open-label, non-inferiority phase 3 study,” The Lancet Oncology, vol. 15, no. 6, pp. 569–579, 2014. View at Google Scholar
  20. D. Strumberg, B. Schultheis, M. E. Scheulen et al., “Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer,” Investigational New Drugs, vol. 30, no. 3, pp. 1138–1143, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. B. K. Reddy, V. Lokesh, M. S. Vidyasagar et al., “Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb , 5-year study in Indian patients,” Oral Oncology, vol. 50, no. 5, pp. 498–505, 2014. View at Google Scholar
  22. E. Tan-Chiu, G. Yothers, E. Romond et al., “Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31,” Journal of Clinical Oncology, vol. 23, no. 31, pp. 7811–7819, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. S. R. Nalluri, D. Chu, R. Keresztes, X. Zhu, and S. Wu, “Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis,” The Journal of the American Medical Association, vol. 300, no. 19, pp. 2277–2285, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. T. K. Choueiri, E. L. Mayer, Y. Je et al., “Congestive heart failure risk in patients with breast cancer treated with bevacizumab,” Journal of Clinical Oncology, vol. 29, no. 6, pp. 632–638, 2011. View at Publisher · View at Google Scholar · View at Scopus
  25. P. Y. Zuo, X. L. Chen, and Y. W. Liu, “Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis,” PLoS ONE, vol. 9, no. 7, Article ID e102484, 2014. View at Google Scholar
  26. A. F. C. Okines, R. E. Langley, L. C. Thompson et al., “Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report,” Annals of Oncology, vol. 24, no. 3, Article ID mds533, pp. 702–709, 2013. View at Publisher · View at Google Scholar · View at Scopus
  27. S. M. Gressett and S. R. Shah, “Intricacies of bevacizumab -induced toxicities and their management,” Annals of Pharmacotherapy, vol. 43, no. 3, pp. 490–501, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. C. S. Fuchs, J. Tomasek, C. J. Yong et al., “Ramucirumab monotherapy for previously treated advanced gastric or gastro- oesophageal junction adenocarcinoma (REGARD): an international, randomised , multicentre , placebo-controlled, phase 3 trial,” The Lancet, vol. 383, no. 9911, pp. 31–39, 2014. View at Google Scholar
  29. A. X. Zhu, R. S. Finn, M. Mulcahy et al., “A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer,” Clinical Cancer Research, vol. 19, no. 23, pp. 6614–6623, 2013. View at Publisher · View at Google Scholar
  30. J. A. Garcia, G. R. Hudes, T. K. Choueiri et al., “A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy,” Cancer, vol. 120, no. 11, pp. 1647–1655, 2014. View at Google Scholar
  31. M. S. Ewer, M. T. Vooletich, J.-B. Durand et al., “Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment,” Journal of Clinical Oncology, vol. 23, no. 31, pp. 7820–7826, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Procter, T. M. Suter, E. de Azambuja et al., “Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial,” Journal of Clinical Oncology, vol. 28, no. 21, pp. 3422–3428, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. X. L. Du, R. Xia, K. Burau, and C. C. Liu, “Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998–2005,” Medical Oncology, vol. 28, supplement 1, pp. S80–S90, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. B. Vahid and A. Mehrotra, “Trastuzumab (Herceptin)-associated lung injury,” Respirology, vol. 11, no. 5, pp. 655–658, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. Herceptin (trastuzumab for injection), FDA approved package insert. US National Library of Medicine, 2010, http://www.dailymed.nlm.nih.gov/.
  36. S. Verma, D. Miles, L. Gianni et al., “Trastuzumabemtansine for HER2-positive advanced breast cance,” The New England Journal of Medicine, vol. 367, no. 19, pp. 1783–1791, 2012. View at Google Scholar
  37. S. Girish, M. Gupta, B. Wang et al., “Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody-drug conjugate in development for the treatment of HER2-positive cancer,” Cancer Chemotherapy and Pharmacology, vol. 69, no. 5, pp. 1229–1240, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Corteś, P. Fumoleau, G. Bianchi et al., “Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer,” Journal of Clinical Oncology, vol. 30, no. 14, pp. 1594–1600, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. L. Gianni, T. Pienkowski, Y. H. Im et al., “Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer ( NeoSphere ): a randomised multicentre , open-label, phase 2 trial,” The Lancet Oncology, vol. 13, pp. 25–32, 2012. View at Google Scholar
  40. J. Abraham and M. Stenger, “Pertuzumab in neoadjuvant treatment of HER2-positive early breast cancer,” Journal of Community and Supportive Oncology, vol. 12, no. 3, pp. 84–86, 2014. View at Google Scholar
  41. A. De Masson, P. Guitera, P. Brice et al., “Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas,” British Journal of Dermatology, vol. 170, no. 3, pp. 720–724, 2014. View at Google Scholar
  42. T. Elter, L. Gercheva-Kyuchukova, H. Pylylpenko et al., “Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial,” The Lancet Oncology, vol. 12, no. 13, pp. 1204–1213, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. H. Lioté, F. Lioté, B. Séroussi et al., “Rituximab-induced lung disease: a systematic literature review,” European Respiratory Journal, vol. 35, no. 3, pp. 681–687, 2010. View at Publisher · View at Google Scholar
  44. O. W. Press, J. M. Unger, L. M. Rimsza et al., “Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus 131iodine-tositumomab for previously untreated follicular non-hodgkin lymphoma: SWOG S0016,” Journal of Clinical Oncology, vol. 31, no. 3, pp. 314–320, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. Y. Ogawa, M. Ogura, T. Suzuki et al., “A phase I/II study of ofatumumab (GSK1841157) in Japanese and Korean patients with relapsed or refractory B-cell chronic lymphocytic leukemia,” International Journal of Hematology, vol. 98, no. 2, pp. 164–170, 2013. View at Publisher · View at Google Scholar · View at Scopus
  46. W. G. Wierda, T. J. Kipps, J. Mayer et al., “Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia,” Journal of Clinical Oncology, vol. 28, no. 10, pp. 1749–1755, 2010. View at Publisher · View at Google Scholar
  47. F. A. Morschhauser, G. Cartron, C. Thieblemont et al., “Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study,” Journal of Clinical Oncology, vol. 31, no. 23, pp. 2912–2919, 2013. View at Google Scholar
  48. J. Radford, A. Davies, G. Cartron et al., “Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (B021000),” Blood, vol. 122, no. 7, pp. 1137–1143, 2013. View at Publisher · View at Google Scholar
  49. F. Morschhauser, J. Radford, A. Van Hoof et al., “90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial,” Journal of Clinical Oncology, vol. 31, no. 16, pp. 1977–1983, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. J. M. Vose, S. Carter, L. J. Burns et al., “Phase III randomized study of rituximab/ carmustine , etoposide , cytarabine , and melphalan (BEAM) compared with iodine-131 tositumomab /BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial,” Journal of Clinical Oncology, vol. 31, pp. 1662–1668, 2013. View at Publisher · View at Google Scholar
  51. B. K. Link, P. Martin, M. S. Kaminski, S. J. Goldsmith, M. Coleman, and J. P. Leonard, “Cyclophosphamide, vincristine, and prednisone followed by tositumomab and iodine-131-tositumomab in patients with untreated low-grade follicular lymphoma: eight-year follow-up of a multicenter phase II study,” Journal of Clinical Oncology, vol. 28, no. 18, pp. 3035–3041, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. M. A. Fanale, A. Forero-Torres, J. D. Rosenblatt et al., “A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies,” Clinical Cancer Research, vol. 18, no. 1, pp. 248–255, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Younes, A. K. Gopal, S. E. Smith et al., “Results of a pivotal phase II study of brentuximabvedotin for patients with relapsed or refractory Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 30, no. 18, pp. 2183–2189, 2012. View at Publisher · View at Google Scholar
  54. T. Siddiqi, S. H. Thomas, and R. Chen, “Role of brentuximabvedotin in the treatment of relapsed or refractory Hodgkin lymphoma,” Pharmacogenomics and Personalized Medicine, vol. 7, pp. 79–85, 2014. View at Publisher · View at Google Scholar
  55. A. Younes, J. M. Connors, S. I. Park et al., “Brentuximabvedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study,” The Lancet Oncology, vol. 14, pp. 1348–1356, 2013. View at Google Scholar
  56. L. A. Fecher, S. S. Agarwala, F. Stephen Hodi, and J. S. Weber, “Ipilimumab and its toxicities: a multidisciplinary approach,” The Oncologist, vol. 18, no. 6, pp. 733–743, 2013. View at Publisher · View at Google Scholar · View at Scopus
  57. F. S. Hodi, S. J. O'Day, D. F. McDermott et al., “Improved survival with ipilimumab in patients with metastaticmelanoma,” The New England Journal of Medicine, vol. 363, pp. 711–723, 2010. View at Google Scholar
  58. M. M. Heiss, P. Murawa, P. Koralewski et al., “The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial,” International Journal of Cancer, vol. 127, no. 9, pp. 2209–2221, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Adami, C. Libanati, S. Boonen et al., “Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial,” Journal of Bone and Joint Surgery A, vol. 94, no. 23, pp. 2113–2119, 2012. View at Publisher · View at Google Scholar · View at Scopus
  60. D. H. Henry, L. Costa, F. Goldwasser et al., “Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma,” Journal of Clinical Oncology, vol. 29, no. 9, pp. 1125–1132, 2011. View at Publisher · View at Google Scholar · View at Scopus
  61. S. L. Topalian, M. Sznol, D. F. McDermott et al., “Survival , durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab,” Journal of Clinical Oncology, vol. 32, no. 10, pp. 1020–1030, 2014. View at Google Scholar
  62. R. Kurzrock, P. M. Voorhees, C. Casper et al., “A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-hodgkin lymphoma, multiple myeloma, or castleman disease,” Clinical Cancer Research, vol. 19, no. 13, pp. 3659–3670, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. M. C. Castells, N. M. Tennant, D. E. Sloane et al., “Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases,” Journal of Allergy and Clinical Immunology, vol. 122, no. 3, pp. 574–580, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. F. Torino, A. Barnabei, L. de Vecchis, R. Salvatori, and S. M. Corsello, “Hypophysitis induced by monoclonal antibodies to cytotoxic T lymphocyte antigen 4: challenges from a new cause of a rare disease,” Oncologist, vol. 17, no. 4, pp. 525–535, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. S. M. Corsello, A. Barnabei, P. Marchetti, L. De Vecchis, R. Salvatori, and F. Torino, “Endocrine side effects induced by immune checkpoint inhibitors,” The Journal of Clinical Endocrinology & Metabolism, vol. 98, no. 4, pp. 1361–1375, 2013. View at Publisher · View at Google Scholar · View at Scopus
  66. S. L. Topalian, F. S. Hodi, J. R. Brahmer et al., “Safety, activity, and immune correlates of anti-PD-1 antibody in cancer,” New England Journal of Medicine, vol. 366, no. 26, pp. 2443–2454, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Ribas, F. S. Hodi, R. Kefford et al., “Efficacy and safety of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients (pts) with melanoma (MEL),” in Proceedings of the American Society of Clinical Oncology Meeting (ASCO '14), 2014, (Abstract LBA9000).
  68. H. Hurwitz, L. Fehrenbacher, W. Novotny et al., “Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer,” The New England Journal of Medicine, vol. 350, no. 23, pp. 2335–2342, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. I. E. Krop, S. B. Kim, A. González-Martín et al., “TH3RESA study collaborators Trastuzumabemtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial,” The Lancet Oncology, vol. 15, no. 7, pp. 689–699, 2014. View at Publisher · View at Google Scholar
  70. P. Madeddu, “Therapeutic angiogenesis and vasculogenesis for tissue regeneration,” Experimental Physiology, vol. 90, no. 3, pp. 315–326, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. E. S. Robinson, E. V. Khankin, T. K. Choueiri et al., “Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors,” Hypertension, vol. 56, no. 6, pp. 1131–1136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. H. Izzedine, S. Ederhy, F. Goldwasser et al., “Management of hypertension in angiogenesis inhibitor-treated patients,” Annals of Oncology, vol. 20, no. 5, pp. 807–815, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. R. Dienstmann, I. Braña, J. Rodon, and J. Taberanero, “Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs,” Oncologist, vol. 16, no. 12, pp. 1729–1740, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. J. A. Garcia, G. R. Hudes, T. K. Choueiri et al., “A phase 2, single-arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy,” Cancer, vol. 120, no. 11, pp. 1647–1655, 2014. View at Publisher · View at Google Scholar
  75. F. A. Scappaticci, J. R. Skillings, S. N. Holden et al., “Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab,” Journal of the National Cancer Institute, vol. 99, pp. 1232–1239, 2007. View at Google Scholar
  76. J.-Y. Pierga, T. Petit, T. Delozier et al., “Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study,” The Lancet Oncology, vol. 13, no. 4, pp. 375–384, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. C. Criscitiello, O. Metzger-Filho, K. S. Saini et al., “Targeted therapies in breast cancer: are heart and vessels also being targeted?” Breast Cancer Research, vol. 14, no. 3, article 209, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. E. Radzikowska, E. Szczepulska, M. Chabowski, and I. Bestry, “Organising pneumonia caused by transtuzumab (Herceptin) therapy for breast cancer,” European Respiratory Journal, vol. 21, no. 3, pp. 552–555, 2003. View at Publisher · View at Google Scholar · View at Scopus
  79. M. J. Pepels, K. A. Boomars, R. van Kimmenade, and P. S. Hupperets, “Life-threatening interstitial lung disease associated with trastuzumab: case report,” Breast Cancer Research and Treatment, vol. 113, no. 3, pp. 609–612, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. H. Izzedine, C. Massard, J. P. Spano, F. Goldwasser, D. Khayat, and J. C. Soria, “VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management,” European Journal of Cancer, vol. 46, no. 2, pp. 439–448, 2010. View at Publisher · View at Google Scholar · View at Scopus
  81. V. Eremina, J. A. Jefferson, J. Kowalewska et al., “VEGF inhibition and renal thrombotic microangiopathy,” The New England Journal of Medicine, vol. 358, no. 11, pp. 1129–1136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. G. Bollée, N. Patey, G. Cazajous et al., “Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib,” Nephrology Dialysis Transplantation, vol. 24, no. 2, pp. 682–685, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. J.-M. Halimi, M. Azizi, G. Bobrie et al., “Vascular and renal effects of anti-angiogenic therapy,” Nephrologie et Therapeutique, vol. 4, no. 7, pp. 602–615, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. R. Pirker, J. R. Pereira, J. von Pawel et al., “EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study,” The Lancet Oncology, vol. 13, no. 1, pp. 33–42, 2012. View at Publisher · View at Google Scholar · View at Scopus
  85. S. E. Borofsky, M. S. Levine, S. E. Rubesin, J. L. Tanyi, C. S. Chu, and A. S. Lev-Toaff, “Bevacizumab-induced perforation of the gastrointestinal tract: clinical and radiographic findings in 11 patients,” Abdominal Imaging, vol. 38, no. 2, pp. 265–272, 2013. View at Publisher · View at Google Scholar · View at Scopus
  86. T. Li and R. Perez-Soler, “Skin toxicities associated with epidermal growth factor receptor inhibitors,” Targeted Oncology, vol. 4, no. 2, pp. 107–119, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. T. Eames, B. Grabein, J. Kroth, and A. Wollenberg, “Microbiological analysis of epidermal growth factor receptor inhibitor therapy-associated paronychia,” Journal of the European Academy of Dermatology and Venereology, vol. 24, no. 8, pp. 958–960, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. M. E. Lacouture, M. J. Anadkat, R.-J. Bensadoun et al., “Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities,” Supportive Care in Cancer, vol. 19, no. 8, pp. 1079–1095, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. F. Kabbinavar, H. I. Hurwitz, L. Fehrenbacher et al., “Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.,” Journal of Clinical Oncology, vol. 21, no. 1, pp. 60–65, 2003. View at Publisher · View at Google Scholar · View at Scopus
  90. C. D. Schweighofer and C.-M. Wendtner, “First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab,” Onco Targets and Therapy, vol. 3, pp. 53–67, 2010. View at Google Scholar · View at Scopus
  91. W. Wang, L. R. Zhao, X. Q. Lin, and F. Feng, “Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancer,” World Journal of Gastroenterology, vol. 20, no. 21, pp. 6691–6697, 2014. View at Publisher · View at Google Scholar
  92. M. B. Atkins, R. R. Kudchadkar, M. Sznol et al., “Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma,” in Proceedings of the American Society of Clinical Oncology Meeting (ASCO '14), 2014, abstract no. 9001.
  93. B. C. Creelan, “Update on immune checkpoint inhibitors in lung cancer,” Cancer Control, vol. 21, no. 1, pp. 80–89, 2014. View at Google Scholar
  94. J. R. Brahmer, S. S. Tykodi, L. Q. M. Chow et al., “Safety and activity of anti-PD-L1 antibody in patients with advanced cancer,” The New England Journal of Medicine, vol. 366, no. 26, pp. 2455–2465, 2012. View at Publisher · View at Google Scholar · View at Scopus
  95. P. A. Ascierto, M. Kalos, D. A. Schaer, M. K. Callahan, and J. D. Wolchok, “Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types,” Clinical Cancer Research, vol. 19, no. 5, pp. 1009–1020, 2013. View at Publisher · View at Google Scholar · View at Scopus